Sökresultat - "albumin‐bound paclitaxel"

Acetyl-lysine human serum albumin nanoparticles activate CD44 receptors, with preferential uptake by cancer stem cells, leading to tumor eradication.

Xiong G; School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom., Schätzlein AG; School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom; Nanomerics Ltd., 6(th) Floor, 2 London Wall Place, London EC2Y 5AU, United Kingdom., Uchegbu IF; School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom; Nanomerics Ltd., 6(th) Floor, 2 London Wall Place, London EC2Y 5AU, United Kingdom; Wolfson College, University of Cambridge, Cambridge CB3 9BB, United Kingdom. Electronic address: ijeoma.uchegbu@ucl.ac.uk.

Journal Article , 2025

Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial.

Liu Z; Cancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China. zhigangliu1983@hotmail.com.; Shenzhen School of Clinical Medicine, Southern Medical University, Guangdong, China. zhigangliu1983@hotmail.com., Wang D; Department of Oral and Maxillofacial Surgery, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China., Li G; Cancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China.; Shenzhen School of Clinical Medicine, Southern Medical University, Guangdong, China., Yi M; Department of Pathology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China., Zhang Z; Cancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China.; Shenzhen School of Clinical Medicine, Southern Medical University, Guangdong, China., Zhong G; Cancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China., Xu L; Cancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China.; Shenzhen School of Clinical Medicine, Southern Medical University, Guangdong, China., Jiang R; Cancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China., Zheng Y; Cancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China., Huang L; Cancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China., Peng Y; Cancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China., Liang L; Department of Oral and Maxillofacial Surgery, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China., Li J; Department of Radiology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China., Liu Y; Department of Pathology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China., Lai J; Department of Pathology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China., Lv X; Department of Pathology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China., Xu Y; Department of Pathology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China., Liu Q; Cancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China., Wang Z; Cancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China., Liu Z; Cancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China., Yang Q; Cancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China., Nie L; Department of Oral and Maxillofacial Surgery, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China., Lei J; Department of Oral and Maxillofacial Surgery, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China.; School of Stomatology Jinan University, Guangzhou, Guangdong, China., Huang X; Cancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China., Liu Z; Cancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China., Jiang W; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Journal Article; Clinical Trial, Phase II; Multicenter Study , 2025

Impact of ABCB1 single-nucleotide variants on early, extremely severe neutropenia induced by paclitaxel/nanoparticle albumin-bound paclitaxel in patients with gastric cancer.

Maeda A; Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan., Matsuo K; Division of Cancer Epidemiology and Prevention, Aichi Cancer Center, Nagoya, Aichi, Japan.; Division of Cancer Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan., Ando H; Department of Cellular and Molecular Function Analysis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan., Morishige JI; Department of Cellular and Molecular Function Analysis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan., Muro K; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan., Uchida K; Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan., Tajika M; Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.

Journal Article , 2025

Risk comparison of adverse reactions between gemcitabine monotherapy and gemcitabine combined with albumin-bound paclitaxel in pancreatic cancer: insights from the FDA Adverse Event Reporting System (FAERS) database.

Jiang P; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China., Zong K; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China., Peng D; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China., Zhou B; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China., Wu Z; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. wzjtcy@126.com.

Journal Article; Comparative Study , 2025

The combination of gemcitabine and albumin-bound paclitaxel effectively inhibits de novo lipogenesis in pancreatic cancer cells by targeting the AMPK/SREBP1 pathway.

Liu G; Department of Biochemistry and Molecular Biology, Harbin Medical University, Harbin 150081, China; Department of Harbin Medical University Cancer Hospital, Harbin 150040, China., Yang D; Department of Biochemistry and Molecular Biology, Harbin Medical University, Harbin 150081, China; Department of Harbin Medical University Cancer Hospital, Harbin 150040, China., Meng J; Department of Biochemistry and Molecular Biology, Harbin Medical University, Harbin 150081, China; Department of Harbin Medical University Cancer Hospital, Harbin 150040, China., He Q; Department of Biochemistry and Molecular Biology, Harbin Medical University, Harbin 150081, China; Department of Harbin Medical University Cancer Hospital, Harbin 150040, China., Wu D; Department of Biochemistry and Molecular Biology, Harbin Medical University, Harbin 150081, China; Department of Harbin Medical University Cancer Hospital, Harbin 150040, China. Electronic address: 1867@hrbmu.edu.cn.

Journal Article , 2025

Impact of tislelizumab combined with albumin-bound paclitaxel and carboplatin on intestinal flora and gastrointestinal toxicities in advanced lung cancer.

Feng K; Department of Thoracic Surgery, Hebei Petrochina Central Hospital, Langfang, Hebei Province, PR China., Liu T; Department of Thoracic Surgery, Hebei Petrochina Central Hospital, Langfang, Hebei Province, PR China., Ren R; Department of Thoracic Surgery, Hebei Petrochina Central Hospital, Langfang, Hebei Province, PR China., Zhao Y; Department of Thoracic Surgery, Hebei Petrochina Central Hospital, Langfang, Hebei Province, PR China., Li H; Department of Thoracic Surgery, Hebei Petrochina Central Hospital, Langfang, Hebei Province, PR China., Wang J; Department of Thoracic Surgery, Hebei Petrochina Central Hospital, Langfang, Hebei Province, PR China.

Journal Article , 2025

A comparison between single and fractionated doses of albumin-bound paclitaxel in the treatment of advanced esophageal cancer: A multicenter case-control study.

Ren J; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China., Wang K; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China., Zhao J; Department of Digestive, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China., Xu C; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China., Liu C; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China., Wang Y; Department of Oncology Digestive, The First Hospital of Shanxi Medical University, Taiyuan, China., Wang G; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Journal Article; Multicenter Study; Comparative Study , 2024

Unveiling the Hidden Risks: An Update Decade-Long Analysis of Abraxane-Related Adverse Events from the FAERS Database.

Zhao YC; Department of Radiation Oncology, The Second Hospital of Jilin University, Changchun, Jilin, People's Republic of China.; NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, Jilin, People's Republic of China., Li X; Department of Radiology, The Second Hospital of Jilin University, Changchun, Jilin, People's Republic of China., Wang CQ; Department of Gynaecology, Aviation General Hospital, Beijing, People's Republic of China., Jiao Y; Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, People's Republic of China., Shen YN; NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, Jilin, People's Republic of China., Wang TJ; Department of Radiation Oncology, The Second Hospital of Jilin University, Changchun, Jilin, People's Republic of China.; NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, Jilin, People's Republic of China., Zhang CH; Department of Hematology and Oncology, The Second Hospital of Jilin University, Changchun, Jilin, People's Republic of China.

Journal Article , 2024

Sintilimab Combined with Nanoparticle Albumin-Bound Paclitaxel-Based Chemotherapy in Severe Locally Advanced or Metastatic Squamous NSCLC Showed Good Efficacy and Safety: A Pilot Retrospective Analysis.

Zhong Y; Department of Respiratory and Critical Care Medicine, Linping Campus, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China., Mao Y; Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China., Fu X; Department of Respiratory and Critical Care Medicine, Linping Campus, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China., Huang H; Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.

Journal Article , 2024

Short-Term Safety Evaluation of Albumin-Bound Paclitaxel in Intraoperative and Postoperative Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer.

Zhou J; Second Clinical College, Wuhan University, Wuhan , Hubei Province, 430070, China.; Department of Gastrointestinal Surgery, the Center for Minimally Invasive Surgery of Gastrointestinal Cancer, Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, Wuhan Peritoneal Cancer Clinical Medical Center, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuchang District, Hubei Province, 430070, China., Cai X; Department of Gastrointestinal Surgery, the Center for Minimally Invasive Surgery of Gastrointestinal Cancer, Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, Wuhan Peritoneal Cancer Clinical Medical Center, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuchang District, Hubei Province, 430070, China., Lu Z; Department of Gastrointestinal Surgery, the Center for Minimally Invasive Surgery of Gastrointestinal Cancer, Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, Wuhan Peritoneal Cancer Clinical Medical Center, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuchang District, Hubei Province, 430070, China., Xiong B; Department of Gastrointestinal Surgery, the Center for Minimally Invasive Surgery of Gastrointestinal Cancer, Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, Wuhan Peritoneal Cancer Clinical Medical Center, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuchang District, Hubei Province, 430070, China., Peng C; Department of Gastrointestinal Surgery, the Center for Minimally Invasive Surgery of Gastrointestinal Cancer, Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, Wuhan Peritoneal Cancer Clinical Medical Center, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuchang District, Hubei Province, 430070, China. whupengcw@whu.edu.cn.

Journal Article , 2024

[Efficacy and safety of programmed death receptor-1 inhibitor combined with albumin-bound paclitaxel and cisplatin in the neoadjuvant treatment of locally advanced head and neck squamous cell carcinoma].

Wu D; Department of Head and Neck Surgery, Center for Cancer Prevention and Control, Sun Yat-sen University, South China State Key Laboratory of Oncology, Collaborative Innovation Center of Oncology, Guangdong Clinical Medical Research Center for Malignant Tumors, Guangzhou 510060, China., Fang Q; Department of Head and Neck Surgery, Center for Cancer Prevention and Control, Sun Yat-sen University, South China State Key Laboratory of Oncology, Collaborative Innovation Center of Oncology, Guangdong Clinical Medical Research Center for Malignant Tumors, Guangzhou 510060, China., Cao F; Department of Head and Neck Surgery, Center for Cancer Prevention and Control, Sun Yat-sen University, South China State Key Laboratory of Oncology, Collaborative Innovation Center of Oncology, Guangdong Clinical Medical Research Center for Malignant Tumors, Guangzhou 510060, China., Zhao Z; Department of Head and Neck Surgery, Center for Cancer Prevention and Control, Sun Yat-sen University, South China State Key Laboratory of Oncology, Collaborative Innovation Center of Oncology, Guangdong Clinical Medical Research Center for Malignant Tumors, Guangzhou 510060, China., Zhang XR; Department of Otorhinolaryngology, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China., Chen CY; Department of Head and Neck Surgery, Center for Cancer Prevention and Control, Sun Yat-sen University, South China State Key Laboratory of Oncology, Collaborative Innovation Center of Oncology, Guangdong Clinical Medical Research Center for Malignant Tumors, Guangzhou 510060, China., Li ZM; Department of Head and Neck Surgery, Center for Cancer Prevention and Control, Sun Yat-sen University, South China State Key Laboratory of Oncology, Collaborative Innovation Center of Oncology, Guangdong Clinical Medical Research Center for Malignant Tumors, Guangzhou 510060, China., Han F; Department of Head and Neck Surgery, Center for Cancer Prevention and Control, Sun Yat-sen University, South China State Key Laboratory of Oncology, Collaborative Innovation Center of Oncology, Guangdong Clinical Medical Research Center for Malignant Tumors, Guangzhou 510060, China., Liu XK; Department of Head and Neck Surgery, Center for Cancer Prevention and Control, Sun Yat-sen University, South China State Key Laboratory of Oncology, Collaborative Innovation Center of Oncology, Guangdong Clinical Medical Research Center for Malignant Tumors, Guangzhou 510060, China.

English Abstract; Journal Article , 2025

Research trend of albumin-bound paclitaxel for the treatment of lung cancer: A 20-year investigation.

Wang L; Department of Radiation Oncology, Chengdu Qingbaijiang District People's Hospital, Chengdu, Sichuan, 610300, China. Electronic address: 353391742@qq.com., Zhao G; Department of General Surgery, Chengdu Qingbaijiang District People's Hospital, Chengdu, Sichuan, 610300, China. Electronic address: 641388114@qq.com., Fang H; Department of Radiation Oncology, Chengdu Qingbaijiang District People's Hospital, Chengdu, Sichuan, 610300, China. Electronic address: 529398954@qq.com., Deng P; Department of Radiation Oncology, Chengdu Qingbaijiang District People's Hospital, Chengdu, Sichuan, 610300, China. Electronic address: dpc8525764233@163.com.

Letter , 2024

Wolf in Sheep's Clothing: Taming Cancer's Resistance with Human Serum Albumin?

Stukan I; Department of General Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland., Żuk A; Independent Laboratory of Community Pharmacy, Pomeranian Medical University in Szczecin, Szczecin, Poland., Pukacka K; Department of Pharmaceutical Technology, Pomeranian Medical University in Szczecin, Szczecin, Poland., Mierzejewska J; Independent Laboratory of Pharmacokinetic and Clinical Pharmacy, Pomeranian Medical University in Szczecin, Szczecin, Poland., Pawłowski J; Independent Laboratory of Pharmacokinetic and Clinical Pharmacy, Pomeranian Medical University in Szczecin, Szczecin, Poland., Kowalski B; Independent Laboratory of Pharmacokinetic and Clinical Pharmacy, Pomeranian Medical University in Szczecin, Szczecin, Poland., Dąbkowska M; Independent Laboratory of Pharmacokinetic and Clinical Pharmacy, Pomeranian Medical University in Szczecin, Szczecin, Poland.

Journal Article; Review , 2025

Factors affecting peripheral neuropathy induced by nanoparticle albumin-bound paclitaxel in patients with pancreatic cancer.

Kang M; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea., Yoo S; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea., Jung Y; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea., Lim H; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea., Lee MH; Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea., Ryu JK; Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea., Lee JI; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea.

Journal Article , 2024

Efficacy and safety of nanoparticle albumin-bound paclitaxel plus carboplatin as neoadjuvant chemotherapy for stages III-IV, unresectable ovarian cancer: a single-arm, open-label, phase Ib/II study.

Yin L; Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China., Jiang W; Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China., Liu S; Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China., Fu Y; Department of Radiology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China., Zhou L; Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China., Pei X; Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China., Ye S; Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China., Shen W; Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China., Yang H; Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China. huijuanyang@hotmail.com., Shan B; Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China. shanboer@126.com.

Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I; Multicenter Study; Research Support, Non-U.S. Gov't , 2024

Exploration of the inhibition action of TPGS on tumor cells and its combined use with chemotherapy drugs.

Tang L; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China., Huang K; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China., Jiang W; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China., Fu L; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China., Zhang R; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China., Shen L; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China., Ou Z; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China., Huang Y; Zhejiang Institute of Dermatology Prevention and Treatment, Huzhou, China., Zhang Z; Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China.

Journal Article , 2023

Myelosuppression Caused by Nanoparticle Albumin-Bound Paclitaxel in the Northern Chinese Population and the Role of Body Composition.

Shi Y; Ordos Clinical College, Baotou Medical College, Ordos, People's Republic of China., Guo J; Ordos Clinical College, Inner Mongolia Medical University, Ordos, People's Republic of China., Jiang Y; Department of Medical Oncology, Ordos Central Hospital, Ordos, People's Republic of China., Zhao J; Department of Medical Oncology, Ordos Central Hospital, Ordos, People's Republic of China., Li J; Ordos Clinical College, Inner Mongolia Medical University, Ordos, People's Republic of China., Shen J; Ordos Clinical College, Baotou Medical College, Ordos, People's Republic of China., Jin G; Department of Medical Oncology, Ordos Central Hospital, Ordos, People's Republic of China., Bai X; Department of Medical Oncology, Ordos Central Hospital, Ordos, People's Republic of China., Li Q; Department of Medical Oncology, Ordos Central Hospital, Ordos, People's Republic of China.

Journal Article , 2023

Revisiting the in-vitro and in-vivo considerations for in-silico modelling of complex injectable drug products.

Dabke A; Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat 390001, India; Formulation Research & Development- Biopharmaceutics, Sun Pharmaceutical Industries Ltd, Vadodara, Gujarat 390012, India., Ghosh S; Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat 390001, India., Dabke P; Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat 390001, India., Sawant K; Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat 390001, India. Electronic address: dr_krutikasawant@rediffmail.com., Khopade A; Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat 390001, India; Formulation Research & Development- Novel Drug Delivery Systems, Sun Pharmaceutical Industries Ltd, Vadodara, Gujarat 390012, India. Electronic address: ajay.khopade@sunpharma.com.

Journal Article; Review , 2023

Safety signals of albumin-bound paclitaxel: Data mining of the Food and Drug Administration adverse event reporting system.

Wang Y; Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, China., Liu X; Department of Gastrointestinal Surgery, The Fifth People's Hospital of Chongqing, Chongqing, China.

Journal Article , 2023

A retrospective study of adjuvant albumin-bound paclitaxel plus S-1 after D2 gastrectomy versus oxaliplatin plus S-1 in gastric cancer.

Li N; The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310001, China., Wu H; The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310001, China., Xu X; The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310001, China., Wei Q; The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310001, China., Ding Y; The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310001, China., Liu S; The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310001, China., Wu J; The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310001, China., Zheng Y; The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310001, China., Xu N; The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310001, China., Gao Y; The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310001, China., Jiang H; The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310001, China. jianghaiping@zju.edu.cn.

Journal Article , 2024